GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is for the treatment of patients with follicular lymphoma who relapsed after OR are refractory to a rituximab-containing regimen Your FL patient previously responded to a rituximab-containing regimen but has relapsed, and now needs further treatment It’s time to consider GAZYVA in combination with bendamustine Indication GAZYVA ® (obinutuzumab), in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen. Boxed WARNINGS: HEPATITIS B VIRUS REACTIVATION AND PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY • Hepatitis B Virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients receiving CD20-directed cytolytic antibodies, including GAZYVA. Screen all patients for HBV infection before treatment initiation. Monitor HBV positive patients during and after treatment with GAZYVA. Discontinue GAZYVA and concomitant medications in the event of HBV reactivation • Progressive Multifocal Leukoencephalopathy (PML) including fatal PML, can occur in patients receiving GAZYVA Please see the following pages for additional Important Safety Information and the brief summary of the full Prescribing Information, including Boxed WARNINGS.